Kate Sleeth

Cancer Research UK — United Kingdom

Medicine · Health Sciences

6h-index558citations35works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

PARP inhibition in cancer therapy(21), DNA and Nucleic Acid Chemistry(10), DNA Repair Mechanisms(8), RNA Interference and Gene Delivery(8), Advanced biosensing and bioanalysis techniques(6)

Publications35 total

Supplementary Figure 2 from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2023Open Access
Supplementary Figure 5 from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2023Open Access
Supplementary Figure 4 from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2023Open Access
Supplementary Figure Legends 1-6 from Imaging DNA Damage <i>In Vivo</i> Using γH2AX-Targeted Immunoconjugates
2023Open Access
Data from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2023Open Access
Supplementary Figures 1-6 from Imaging DNA Damage <i>In Vivo</i> Using γH2AX-Targeted Immunoconjugates
2023Open Access
Supplementary Figure 7 from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2023Open Access
Supplementary Figure 2 from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2023Open Access
Data from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2023Open Access
Supplementary Figure 7 from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2023Open Access
Supplementary Figure 1 from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2023Open Access
Supplementary Figure 6 from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2023Open Access
Supplementary Figures 1-6 from Imaging DNA Damage <i>In Vivo</i> Using γH2AX-Targeted Immunoconjugates
2023Open Access
Supplementary Figure 4 from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2023Open Access
Supplementary Table 1 from Imaging DNA Damage <i>In Vivo</i> Using γH2AX-Targeted Immunoconjugates
2023Open Access
Supplementary Figure 1 from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2023Open Access
Supplementary Figure 3 from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2023Open Access
Supplementary Figure Legends 1-6 from Imaging DNA Damage <i>In Vivo</i> Using γH2AX-Targeted Immunoconjugates
2023Open Access
Supplementary Figure 6 from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2023Open Access
Supplementary Tables 1-2 from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2023Open Access
page 1 of 2Next →

Frequent Co-authors

Natalia Issaeva(21), Thomas Helleday(21), Ponnari Gottipati(20), Ricky A. Sharma(20), Huw D. Thomas(19), Tatjana Djurenovic(19), Janneke E. Jaspers(19), Ivaylo Stoimenov(19), Suzanne Kyle(19), Nicholas Pedley(19), Rafal Zur(19), Vicky Chatzakos(19), Evan A. Mulligan(19), Cecilia Lundin(19), Evgenia Gubanova(19), Ariena Kersbergen(19), Adrian L. Harris(19), Sven Rottenberg(19), Nicola J. Curtin(19), Bart Cornelissen(11)